Free Trial
→ Yesterday's deadline changed everything (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$1.62
-2.4%		$2.26
$1.60
▼
$12.30
$1.78M1.16892,751 shs22,386 shs
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
$1.43
-2.1%		$1.45
$1.17
▼
$13.25
$6.54M1.1855,642 shs11,986 shs
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$3.49
-7.4%		$5.27
$2.43
▼
$21.60
$7.94M0.6161,868 shs37,695 shs
LianBio stock logo
LIAN
LianBio
$0.04
$0.05
$0.27
▼
$4.99
$4.80M0.231.04 million shsN/A
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
-2.41%-9.75%-26.36%-48.57%-81.55%
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
-2.05%+2.14%-4.54%-8.92%-78.66%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-7.43%+13.31%+10.79%-40.49%-75.74%
LianBio stock logo
LIAN
LianBio
0.00%-26.00%-27.57%-7.69%-36.22%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$1.62
-2.4%		$2.26
$1.60
▼
$12.30
$1.78M1.16892,751 shs22,386 shs
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
$1.43
-2.1%		$1.45
$1.17
▼
$13.25
$6.54M1.1855,642 shs11,986 shs
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$3.49
-7.4%		$5.27
$2.43
▼
$21.60
$7.94M0.6161,868 shs37,695 shs
LianBio stock logo
LIAN
LianBio
$0.04
$0.05
$0.27
▼
$4.99
$4.80M0.231.04 million shsN/A
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
-2.41%-9.75%-26.36%-48.57%-81.55%
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
-2.05%+2.14%-4.54%-8.92%-78.66%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-7.43%+13.31%+10.79%-40.49%-75.74%
LianBio stock logo
LIAN
LianBio
0.00%-26.00%-27.57%-7.69%-36.22%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
2.67
Moderate Buy$44.002,616.05% Upside
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
1.00
SellN/AN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
2.00
Hold$22.50544.70% Upside
LianBio stock logo
LIAN
LianBio
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CANF, LEXX, ENVB, and LIAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/15/2026
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
10/2/2026
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
9/29/2026
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
9/16/2026
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 10/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$405K4.28N/AN/A$1.76 per share0.92
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/AN/AN/AN/A$7.00 per shareN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$194K37.89N/AN/A$2.00 per share1.75
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/A$2.71 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
-$7.63M-$14.80N/AN/AN/AN/AN/AN/AN/A
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
-$8.77M-$12.65N/AN/AN/AN/A-168.04%-145.95%11/12/2026 (Estimated)
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-$11.90M-$5.10N/AN/AN/AN/A-174.93%-143.89%N/A
LianBio stock logo
LIAN
LianBio
-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/A

Latest CANF, LEXX, ENVB, and LIAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/A-$0.76N/A-$0.76N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
N/AN/AN/AN/AN/A
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/AN/AN/AN/AN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
N/AN/AN/AN/AN/A
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
N/A
2.93
N/A
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/A
10.21
10.21
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
N/A
10.61
10.61
LianBio stock logo
LIAN
LianBio
N/A
10.06
10.06

Institutional Ownership

CompanyInstitutional Ownership
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
21.00%
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
13.82%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
13.06%
LianBio stock logo
LIAN
LianBio
74.85%

Insider Ownership

CompanyInsider Ownership
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
0.80%
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
2.41%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
8.39%
LianBio stock logo
LIAN
LianBio
7.59%
CompanyEmployeesShares OutstandingFree FloatOptionable
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
51.07 millionN/ANot Optionable
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
64.48 million4.37 millionNot Optionable
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
72.11 million1.93 millionNot Optionable
LianBio stock logo
LIAN
LianBio
110108.06 million99.86 millionNot Optionable

Recent News About These Companies

LianMedical (Formerly Known as LianBio) Announces Completion of Merger Between LianBio and LianMedical
July 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/lianmedical-formerly-known-lianbio-announces-082800186.html
MeiraGTx Holdings PLC
May 3, 2025  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/mgtx/company-profile?pid=204345306
With Kezar stranded in lupus limbo, Concentra spies opportunity for next acquisition
October 9, 2024  |  fiercebiotech.comF
China's Zeekr prices US IPO at top of range to raise $441 million
May 10, 2024  |  msn.comhttps://www.msn.com/en-gb/money/other/chinas-zeekr-prices-us-ipo-at-top-of-range-to-raise-441-million/ar-BB1m9yBO
Exclusive-China's Zeekr prices US IPO at top of range to raise $441 million, source says
May 9, 2024  |  msn.comhttps://www.msn.com/en-gb/money/other/exclusive-china-s-zeekr-prices-us-ipo-at-top-of-range-to-raise-441-million-source-says/ar-BB1m7kDW
LianBio to shut down, return cash to investors
February 14, 2024  |  biopharmadive.comB
LianBio Announces Wind Down Of Operations, Workforce Reduction; Stock Up In Pre-Market
February 13, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/lianbio-announces-wind-down-of-operations-workforce-reduction-stock-up-in-pre-market-1033061494
LianBio to Wind Down Operations, Declares Special Dividend
February 13, 2024  |  marketwatch.comhttps://www.marketwatch.com/story/lianbio-to-wind-down-operations-declares-special-dividend-22ab064c
LianBio Shares Gain After Co Announces Plans to Wind Down
February 13, 2024  |  marketwatch.comhttps://www.marketwatch.com/story/lianbio-shares-gain-after-co-announces-plans-to-wind-down-0b565e81
LianBio Announces Completion of Strategic Review
February 13, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/lianbio-announces-completion-strategic-review-120000015.html?.tsrc=rss
B of A Securities Downgrades LianBio: Here's What You Need To Know
January 3, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/b-of-a-securities-downgrades-lianbio-here-s-what-you-need-to-know-1032940825
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
December 26, 2023  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/nanobiotix-partner-lianbio-assigns-its-development-and-commercialization-rights-for-nbtxr3-in-china-and-other-asian-markets-1032925227
LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets
December 26, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/lianbio-enters-agreement-assigning-rights-070000701.html?.tsrc=rss
Interest Is Growing for Smaller, More Speculative Names
December 20, 2023  |  realmoney.thestreet.comhttps://realmoney.thestreet.com/investing/interest-is-growing-for-smaller-more-speculative-names-16140581
LianBio Announces Departure of Chief Financial Officer
December 20, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/lianbio-announces-departure-chief-financial-130000908.html?.tsrc=rss
LianBio Names Stone as Interim CEO as Wang Resigns
December 19, 2023  |  marketwatch.comhttps://www.marketwatch.com/story/lianbio-names-stone-as-interim-ceo-as-wang-resigns-8bc481e8
LianBio Announces Departure of Chief Executive Officer
December 19, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/lianbio-announces-departure-chief-executive-210500865.html?.tsrc=rss
LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences
December 6, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/lianbio-board-directors-unanimously-determines-210500459.html?.tsrc=rss
LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
December 1, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/lianbio-confirms-receipt-unsolicited-proposal-210500043.html?.tsrc=rss
LianBio (LIAN) Reports Q3 2023 Financial Results: Strategic Review in Progress Amid Clinical ...
November 14, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/lianbio-lian-reports-q3-2023-003534652.html?.tsrc=rss

New MarketBeat Followers Over Time

Media Sentiment Over Time

Can-Fite BioPharma stock logo

Can-Fite BioPharma NYSE:CANF

$1.62 -0.04 (-2.41%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$1.65 +0.03 (+1.98%)
As of 10/30/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Enveric Biosciences stock logo

Enveric Biosciences NASDAQ:ENVB

$1.43 -0.03 (-2.05%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$1.38 -0.04 (-3.15%)
As of 10/30/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Lexaria Bioscience stock logo

Lexaria Bioscience NASDAQ:LEXX

$3.49 -0.28 (-7.43%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$3.48 -0.01 (-0.14%)
As of 10/30/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

LianBio stock logo

LianBio NASDAQ:LIAN

$0.04 0.00 (0.00%)
As of 10/30/2026

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas